ATE168415T1 - Wasserlösliche peptidanaloguen mit bindungstellen - Google Patents

Wasserlösliche peptidanaloguen mit bindungstellen

Info

Publication number
ATE168415T1
ATE168415T1 AT91909574T AT91909574T ATE168415T1 AT E168415 T1 ATE168415 T1 AT E168415T1 AT 91909574 T AT91909574 T AT 91909574T AT 91909574 T AT91909574 T AT 91909574T AT E168415 T1 ATE168415 T1 AT E168415T1
Authority
AT
Austria
Prior art keywords
complement
water soluble
binding sites
peptide analogues
directed
Prior art date
Application number
AT91909574T
Other languages
English (en)
Inventor
Thomas Hebell
Douglas T Fearon
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of ATE168415T1 publication Critical patent/ATE168415T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Led Devices (AREA)
  • Led Device Packages (AREA)
AT91909574T 1990-04-25 1991-04-25 Wasserlösliche peptidanaloguen mit bindungstellen ATE168415T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51329990A 1990-04-25 1990-04-25

Publications (1)

Publication Number Publication Date
ATE168415T1 true ATE168415T1 (de) 1998-08-15

Family

ID=24042678

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91909574T ATE168415T1 (de) 1990-04-25 1991-04-25 Wasserlösliche peptidanaloguen mit bindungstellen

Country Status (8)

Country Link
US (1) US6458360B1 (de)
EP (1) EP0528926B1 (de)
JP (1) JPH05507197A (de)
AT (1) ATE168415T1 (de)
AU (1) AU7876691A (de)
CA (1) CA2081207A1 (de)
DE (1) DE69129803D1 (de)
WO (1) WO1991016437A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5709859A (en) * 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
GB9424631D0 (en) * 1994-12-06 1995-01-25 Lynxvale Ltd Modulating the immune response
BR9707325A (pt) 1996-02-09 1999-04-13 Amgen Inc Processo para o tratamento de um paciente afetado com uma doença mediada por il-1, composição farmacéutica e uso da mesma
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
GB9614871D0 (en) 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
CA2273852C (en) 1996-12-06 2009-09-29 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
AU3066699A (en) 1998-03-03 1999-09-20 Johns Hopkins University, The Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
EP1387697A4 (de) * 2001-05-17 2005-04-20 Jolla Pharma Verfahren zur behandlung von antikörper-vermittelten erkrankungen unter verwendung von mitteln zur hemmung von cd21
ES2392511T3 (es) * 2002-11-15 2012-12-11 Musc Foundation For Research Development Moduladores de complemento dianas sobre el receptor 2 de complemento
US20060140939A1 (en) * 2003-02-21 2006-06-29 Fung Sek C M Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
US8454963B2 (en) * 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
US8124097B2 (en) * 2004-01-21 2012-02-28 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
PT1713503E (pt) * 2004-02-10 2013-11-14 Nat Jewish Health Inibição do factor b, a via alternativa do complemento e métodos relacionados
WO2005116071A2 (en) * 2004-05-28 2005-12-08 University Of Massachusetts Snares for pathogenic or infectious agents and uses related thereto
ES2548700T3 (es) * 2005-05-26 2015-10-20 The Regents Of The University Of Colorado, A Body Corporate Inhibición de la vía alternativa del complemento para el tratamiento de lesión cerebral traumática, lesión de médula espinal y afecciones relacionadas
WO2007045465A1 (en) 2005-10-21 2007-04-26 F. Hoffmann-La Roche Ag Method for the recombinant expression of a polypeptide
CN101563363B (zh) 2006-06-21 2013-01-02 南卡罗来纳医疗大学研究发展基金会 用于治疗疾病的靶向补体因子h
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
CA2666843C (en) * 2006-10-20 2015-06-16 Celldex Therapeutics, Inc. Treatment of age-related macular degeneration and other diseases of the eye
EP2236518B1 (de) 2007-03-14 2014-08-06 Alexion Cambridge Corporation Humanisierter Antikörper gegen Faktor B
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
RS20120461A1 (en) 2009-07-02 2013-06-28 Musc Foundation For Research Development METHODS FOR STIMULATION OF LIVER REGENERATION
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
AU2010314931A1 (en) 2009-11-05 2012-06-21 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
HUE046670T2 (hu) 2010-01-15 2020-03-30 Kirin Amgen Inc Anti IL-17RA ellenanyag kiszerelés és terápiás rendek pikkelysömör kezelésére
JP5986990B2 (ja) 2010-05-14 2016-09-06 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート 改善された補体レセプター２（ｃｒ２）ターゲティング基
WO2011163412A1 (en) 2010-06-22 2011-12-29 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the c3d fragment of complement component 3
CN103237557A (zh) 2010-09-15 2013-08-07 赛尔戴克斯治疗公司 用可溶性I型补体受体(sCR1)治疗慢性肾病
CA2815237C (en) 2010-10-27 2018-10-09 Celldex Therapeutics, Inc. Method of improving transplant function using soluble complement receptor type i (scr1)
US20120148542A1 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
EP2855529A4 (de) 2012-05-24 2015-12-09 Alexion Pharma Inc Humanisierte anti-faktor-b-antikörper
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
WO2014106001A2 (en) * 2012-12-28 2014-07-03 Abbvie, Inc. Dual specific binding proteins having a receptor sequence
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
AU2015241373B2 (en) 2014-03-31 2020-11-05 Amgen K-A, Inc. Methods of treating nail and scalp psoriasis
US20160060360A1 (en) 2014-07-24 2016-03-03 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
NZ191320A (en) 1978-09-07 1982-09-14 Beecham Group Ltd In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions
EP0028489B1 (de) 1979-11-05 1983-10-05 Beecham Group Plc Enzym-Derivate und ihre Herstellung
US4642284A (en) 1983-06-13 1987-02-10 Scripps Clinic And Research Foundation Method and system for detection of complement pathway activation
US4672044A (en) 1984-08-24 1987-06-09 Scripps Clinic & Research Foundation Murine monoclonal antibody combining site to human C3b receptor (CR1)
US4761371A (en) 1985-02-12 1988-08-02 Genentech, Inc. Insulin receptor
JPH0742235B2 (ja) 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4894226A (en) 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
ATE114723T1 (de) 1987-03-02 1994-12-15 Enzon Lab Inc Organismus als träger für ''single chain antibody domain (scad)''.
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
ZA89430B (en) 1988-01-22 1989-10-25 Gen Hospital Corp Cloned genes encoding ig-cd4 fusion proteins and the use thereof
EP0325224B1 (de) * 1988-01-22 1996-07-31 ZymoGenetics, Inc. Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US4937183A (en) 1988-02-03 1990-06-26 Cytogen Corporation Method for the preparation of antibody-fragment conjugates
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
IL89790A (en) * 1988-04-01 2002-05-23 Johns Hopking University Sequences of nucleic acids encoding and cells producing CR1 protein and methods for its production and purification
AU4341189A (en) 1988-10-03 1990-05-01 Scripps Clinic And Research Foundation The receptor binding region of ebvgp350
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
AT402153B (de) 1989-06-26 1997-02-25 Immuno Ag Protein-s-hältige pharmazeutische präparation
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins

Also Published As

Publication number Publication date
DE69129803D1 (de) 1998-08-20
EP0528926A1 (de) 1993-03-03
AU7876691A (en) 1991-11-11
US6458360B1 (en) 2002-10-01
CA2081207A1 (en) 1991-10-26
JPH05507197A (ja) 1993-10-21
WO1991016437A1 (en) 1991-10-31
EP0528926B1 (de) 1998-07-15

Similar Documents

Publication Publication Date Title
ATE168415T1 (de) Wasserlösliche peptidanaloguen mit bindungstellen
ATE194382T1 (de) Neuartige polypeptide zur unterstützung der zellfixierung
DK1642973T3 (da) Terapeutisk anvendelser af BR43X2-oplöselige receptorer
ATE136908T1 (de) Peptide und antikörper, die die integrin- ligandbindung inhibieren
Bailey et al. Partial characterization of a second basement membrane collagen in human placenta: evidence for the existence of two type IV collagen molecules
DK161015C (da) Blanding til anvendelse ved ekstern paavisning og lokalisering af en blodprop
IL96043A0 (en) Polypeptides complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
ATE229342T1 (de) Verwendung von interleukin-15
DE69132275D1 (de) Beta-type ähnlicher transformierender wachstumfaktor
KR950704489A (ko) 인터페론 타우 조성물 및 사용방법(interferon tau compositions and methods of use)
ES550943A0 (es) Un procedimiento para preparar una proteina de fusion derivada de la secuencia de aminoacidos de la preprorrelaxina humana.
DE68927379D1 (de) Plättchen blockierende peptide
EA200000685A1 (ru) Комплекс ifnar2/ifn
DK611386A (da) Recombinant humant fsh, fremgangsmaade til fremstilling deraf og vektorer og celler til anvendelse ved fremgangsmaaden
DE69331501D1 (de) Unterdrückung der Proliferation von T-Zellen mittels Peptidfragmenten des basischen Proteins aus Myelin
ATE223481T1 (de) Peptid der löslichen form von acetylcholinesterase mit aktivität als calciumkanalmodulator
ES2129120T3 (es) Un receptor de celulas t humanas de la familia de receptores acoplados a la proteina g.
DK0404967T3 (da) Rekombinante C-terminal-alfa-amiderende enzym af human skjoldbruskkirtel-oprindelse
Benhamini et al. Immunochemical studies with synthetic peptides related to collagen
DE69032096D1 (de) Antikörper gegen das carboxy-terminale Peptid des Somatotropin-Bindungsproteins der Ratte
JPS6460388A (en) Gene coding linked material of protein a-like substance fc bond region, recombinant plasmid containing said gene and transformant produced by using said recombinant plasmid
KR970061914A (ko) 생물학적으로 유용한 펩타이드
EA199900432A1 (ru) Ice-ингибирующие пептиды

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties